Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Durect Corp chart...

About the Company

durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use

CEO

James Brown

Exchange

NASDAQ

Website

http://www.durect.com/

$14M

Total Revenue

103

Employees

$297M

Market Capitalization

-0.63

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $DRRX News

Durect Corp DRRX

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

DURECT and Charles River enter agreement for alzet in U.S., Canada

14d ago, source: Hosted on MSN

DURECT Corporation (NASDAQ:DRRX) entered into a co-marketing and collaboration agreement with Charles River Laboratories for the alzet Osmotic Pumps Portfolio and Associated Product Line in the U ...

DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line

15d ago, source: Business Insider

(RTTNews) - Biopharmaceutical company DURECT Corp. (DRRX) announced Monday that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. (CRL) ...

DRRX Apr 2024 0.500 put

2d ago, source: Yahoo Finance

DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET® Osmotic Pumps Portfolio and ...

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

1mon ago, source: Nasdaq

A link to the webcast will also be available by accessing DURECT's homepage at www.durect.com and clicking on the "Events" page under the "Investors" section. Management will be available for ...

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

15d ago, source: Yahoo Finance

March 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET ...

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

15d ago, source: Stockhouse

Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...